Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial

Area of Science:

• Cardiovascular Research
• Pulmonary Medicine
• Pharmacology

Background:

• Chronic obstructive pulmonary disease (COPD) is associated with systemic inflammation and impaired endothelial function.
• Statins are primarily used for cardiovascular disease prevention but may have pleiotropic effects.
• The impact of statins on vascular and pulmonary function in COPD is not fully understood.

Purpose of the Study:

• To investigate the effects of rosuvastatin on endothelium-dependent vascular function, pulmonary function, and systemic inflammation in COPD patients.
• To assess changes in reactive hyperaemia index, forced expiratory volume in 1 s (FEV1), interleukin-6 (IL6), and high-sensitivity C-reactive protein (hsCRP).

Main Methods:

• A randomized, placebo-controlled, double-blind, parallel trial was conducted with 99 stable COPD patients.
• Participants received either rosuvastatin 10 mg daily or a placebo for 12 weeks.
• Vascular function, pulmonary function (FEV1, FEV1/FVC), and inflammatory markers (IL6, hsCRP) were measured.

Main Results:

• No significant difference in overall vascular or pulmonary function between rosuvastatin and placebo groups.
• Rosuvastatin significantly reduced hsCRP levels and attenuated the rise in IL6 compared to placebo.
• In patients with high hsCRP, rosuvastatin improved endothelium-dependent vascular function.

Conclusions:

• Rosuvastatin treatment significantly reduces systemic inflammation in stable COPD patients.
• In COPD patients with systemic inflammation, rosuvastatin can improve endothelial-dependent vascular function.
• These findings suggest potential therapeutic benefits of statins in COPD, particularly in those with inflammatory markers.